Alnylam Pharmaceuticals
ALNY

$246.78

1.87%

Market Cap: $31.7B

About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Employees: 2,100

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 34 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

72% more capital invested

Capital invested by funds: $16.9B [Q1] → $29.1B (+$12.2B) [Q2]

37% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 63

17% more call options, than puts

Call options by funds: $703M | Put options by funds: $600M

16% more repeat investments, than reductions

Existing positions increased: 190 | Existing positions reduced: 164

4.92% more ownership

Funds ownership: 89.87% [Q1] → 94.8% (+4.92%) [Q2]

5% more funds holding

Funds holding: 488 [Q1] → 511 (+23) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q1] → 6 (-2) [Q2]

See Fund Rankings

Research analyst outlook

34 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$150

39%

downside

Avg. target

$284

15%

upside

High target

$400

62%

upside

34 analyst ratings

24 positive

71%

10 neutral

29%

0 negative

0%

RBC Capital Luca Issi 33% 1-year accuracy 16 / 48 met price target	22%upside $300	Outperform Reiterated	4 Sept 2024
B of A Securities Tazeen Ahmad 57% 1-year accuracy 13 / 23 met price target	24%upside $307	Buy Maintained	4 Sept 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	62%upside $400	Buy Reiterated	30 Aug 2024
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target	13%upside $280	Neutral Maintained	26 Aug 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	62%upside $400	Buy Reiterated	20 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about ALNY published over the past 30 days

Zacks Investment Research

ALNY Down Despite Positive Data From Heart Disease Drug Study

Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.

ALNY Down Despite Positive Data From Heart Disease Drug Study

Steward Health Care and Medical Properties Trust Reach Settlement Agreement in Principle, Allowing for Steward-Operated Hospitals to Be Transitioned to New Ownership

DALLAS--(BUSINESS WIRE)--Steward Health Care (“Steward”), the country's largest physician-led, minority-owned, integrated health care system, announced today it has reached an agreement in principle with its landlord, Medical Properties Trust, Inc. (“MPT”), supported by the “FILO” secured lenders under its funded debt and the official committee of unsecured creditors. Following Bankruptcy Court approval, the agreement allows for the transfer of hospitals that are governed by MPT's master lease.

Steward Health Care and Medical Properties Trust Reach Settlement Agreement in Principle, Allowing for Steward-Operated Hospitals to Be Transitioned to New Ownership

Alnylam: HELIOS-B Success Priced In Already

Alnylam's stock surged due to positive HELIOS-B trial results, but lacked additional upside today after the company presented the data at the ESC congress. Amvuttra shows competitive efficacy and safety in ATTR amyloidosis, with the potential to rival Pfizer's Vyndaqel and other emerging treatments. I believe HELIOS-B's success is priced in at current levels and that further upside is limited in the near term.

Alnylam: HELIOS-B Success Priced In Already

Kern Subbasin Groundwater Sustainability Agencies Urge State to Consider Updated Plan

BAKERSFIELD, Calif.--(BUSINESS WIRE)--The Kern Subbasin Groundwater Sustainability Agencies (GSAs) have responded to a draft report from the California State Water Resources Control Board (SWRCB). The draft report finds the Kern subbasin's Groundwater Sustainability Plan (GSP) to be inadequate and recommends that the subbasin be placed on probation. The GSAs' response was submitted during public workshops held on August 26, 2024, and August 29, 2024, and highlighted the significant improvements.

Kern Subbasin Groundwater Sustainability Agencies Urge State to Consider Updated Plan

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles

Friday, Alnylam Pharmaceuticals Inc. ALNY stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Topline data was revealed in June.

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles

Investors Business Daily

Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations

Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.

Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations

Alnylam shares slide after heart drug data fails to impress investors

Alnylam Pharmaceuticals' shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations.

Alnylam shares slide after heart drug data fails to impress investors

Western Asset Inflation-Linked Income Fund (WIA or “the Fund”; CUSIP: 95766Q106) Announces Notification of Sources of Distributions

NEW YORK--(BUSINESS WIRE)--Category: Distribution Related.

Western Asset Inflation-Linked Income Fund (WIA or “the Fund”; CUSIP: 95766Q106) Announces Notification of Sources of Distributions

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Result.

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 9:30 am ET in Boston Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 1:05 pm ET in New York City A live audio webcast of each presentation will be available on the Inves.

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

See News Rankings